Rheumatoid Arthritis (RA) is a common systemic autoimmune disease affecting between 0.5-1% of the adult population. RA is characterised by inflammation of the synovial joints which can lead to progressive joint destruction and consequently impair quality of life.
Axis-Shield offers a definitive test for early detection of this debilitating disease through the measurement of antibodies to cyclic citrullinated peptides (anti-CCP).
It is generally accepted that early intervention is vital in preventing irreversible joint damage and therefore it is important to diagnose RA as early in the disease course as possible.
New classification criteria for RA were published in 2010. These revised criteria have been approved by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). These new RA classification criteria follow recommendations at the 2009 ACR Congress and will allow clinicians to focus on the important need for earlier diagnosis and more effective early therapeutic intervention. The outcome of the new criteria means that testing for ACPA (principally anti-CCP antibodies) has been added to the biochemical criteria for disease classification, in addition to the long established sole blood test, the relatively non-specific Rheumatoid Factor assay.
This formally recognised the importance of testing for anti-CCP antibodies in the early detection of RA from the major global authorities on this potentially debilitating disease. Anti-CCP is a key product for Axis-Shield, supported by significant IP protection.
For more details on our Anti-CCP assay, please visit the Anti-CCP page.